Article

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

2012-01-01

Abstract excerpt

Recently, the importance of targeted covalent inhibitors in addressing potency, selectivity and drug resistance has become of great interest, especially in the area of non-small cell lung cancer (NSCLC). Although several covalent EGFR TKIs that are advancing in NSCLC clinical development are active against mutations which are refractory to the reversible TKI drugs Tarceva and Iressa, limited chemical diversity has...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5c5f732a-ac08-516a-82ea-4fd332e18375
DOI: 10.1039/c2md20017a

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistanceDOI 10.1039/c2md20017aRead

Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.Semantic proximity Read

Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.Semantic proximity Read

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.Semantic proximity Read

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLCSemantic proximity Read

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.Semantic proximity Read

Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Semantic proximity Read

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.Semantic proximity Read

Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.Semantic proximity Read

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.Semantic proximity Read

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.Semantic proximity Read

Noncovalent wild-type-sparing inhibitors of EGFR T790M.Semantic proximity Read

Design and Synthesis of Non-Covalent Imidazo[1,2-a]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment.Semantic proximity Read